CA2573400A1 - Cyclosporins to treat alzheimer's disease - Google Patents

Cyclosporins to treat alzheimer's disease Download PDF

Info

Publication number
CA2573400A1
CA2573400A1 CA002573400A CA2573400A CA2573400A1 CA 2573400 A1 CA2573400 A1 CA 2573400A1 CA 002573400 A CA002573400 A CA 002573400A CA 2573400 A CA2573400 A CA 2573400A CA 2573400 A1 CA2573400 A1 CA 2573400A1
Authority
CA
Canada
Prior art keywords
ciclosporin
meleu
hydroxy
val
cyclophilin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002573400A
Other languages
English (en)
French (fr)
Inventor
Dalia Cohen
Larry Alexander Gaither
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2573400A1 publication Critical patent/CA2573400A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002573400A 2004-07-13 2005-07-12 Cyclosporins to treat alzheimer's disease Abandoned CA2573400A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58777004P 2004-07-13 2004-07-13
US60/587,770 2004-07-13
PCT/EP2005/007556 WO2006005580A1 (en) 2004-07-13 2005-07-12 Cyclosporins to treat alzheimer’s disease

Publications (1)

Publication Number Publication Date
CA2573400A1 true CA2573400A1 (en) 2006-01-19

Family

ID=35276396

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002573400A Abandoned CA2573400A1 (en) 2004-07-13 2005-07-12 Cyclosporins to treat alzheimer's disease

Country Status (10)

Country Link
EP (1) EP1893226A1 (es)
JP (1) JP2008512351A (es)
KR (1) KR20070036127A (es)
CN (1) CN1984670A (es)
AU (2) AU2005261838A1 (es)
BR (1) BRPI0513317A (es)
CA (1) CA2573400A1 (es)
MX (1) MX2007000502A (es)
RU (1) RU2007105141A (es)
WO (1) WO2006005580A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5322647B2 (ja) 2005-09-30 2013-10-23 スシネキス インク ウイルス感染の治療及び予防のためのシクロスポリンａのアリールアルキル及びヘテロアリールアルキル誘導体
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
ATE502633T1 (de) 2006-05-19 2011-04-15 Scynexis Inc Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
US20100291074A1 (en) * 2007-07-27 2010-11-18 Columbia University In The City Of New York Cyclophilin d-amyloid beta interaction potentiates mitochondrial dysfunction in a transgenic mouse model of alzheimer's disease
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
WO2010002428A2 (en) * 2008-06-06 2010-01-07 Scynexis, Inc. Novel macrocyclic peptides
AU2009334790B2 (en) 2008-12-31 2016-09-08 Scynexis, Inc. Derivatives of cyclosporin A
EP2509615A1 (en) * 2009-12-09 2012-10-17 Scynexis, Inc. Novel cyclic peptides
KR20120035622A (ko) * 2010-10-06 2012-04-16 서울대학교산학협력단 Ｖｄａｃ1 단백질 조절을 통한 파킨슨씨병 치료방법
CN102586121B (zh) * 2012-02-21 2013-07-10 淮海工学院 一种产乙酰胆碱酯酶抑制剂的真菌及其用途
EP2900684A2 (en) 2012-09-29 2015-08-05 Novartis AG Cyclic peptides and use as medicines
EP2908841A4 (en) * 2012-10-19 2016-05-25 Scynexis Inc NEW ANTIVIRAL MACROCYCLES
CN106620648A (zh) * 2016-12-30 2017-05-10 山东景源生物科技有限公司 一种阻断帕金森患者淋巴细胞周期的药物及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0484281B2 (en) * 1990-11-02 2000-11-22 Novartis AG Cyclosporins
JP3089350B2 (ja) * 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド シクロフィリンロタマーゼ活性の阻害剤
US20030103959A1 (en) * 2001-06-22 2003-06-05 Hughes Paul E. Methods of providing neuroprotection and/or neurorestoration via the neural activin type IIB receptor

Also Published As

Publication number Publication date
RU2007105141A (ru) 2008-08-20
WO2006005580A1 (en) 2006-01-19
AU2009210375A1 (en) 2009-09-10
AU2005261838A1 (en) 2006-01-19
EP1893226A1 (en) 2008-03-05
KR20070036127A (ko) 2007-04-02
CN1984670A (zh) 2007-06-20
BRPI0513317A (pt) 2008-05-06
JP2008512351A (ja) 2008-04-24
MX2007000502A (es) 2007-03-08

Similar Documents

Publication Publication Date Title
CA2573400A1 (en) Cyclosporins to treat alzheimer's disease
Pickrell et al. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson’s disease
Dagda et al. Beyond the mitochondrion: cytosolic PINK 1 remodels dendrites through Protein Kinase A
Bowie et al. TTBK2 and primary cilia are essential for the connectivity and survival of cerebellar Purkinje neurons
US20080058276A1 (en) Alzheimer's disease therapeutics based on pin-1 catalyzed conformational changes in phosphorylated amyloid precursor protein
WO2000048621A2 (en) Methods and compositions for regulating protein-protein interactions
WO2013181618A2 (en) Methods to treat alzheimer's disease using apoe inhibitors
US20220226307A1 (en) Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
AU2022291659A1 (en) Tripartite modulators of endosomal G protein-coupled receptors
JP2002522012A (ja) プロテインキナーゼｃイプシロンを欠如する細胞及び動物
Kesavapany et al. Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5
Christner et al. FKBP ligands as novel therapeutics for neurological disorders
US20080300178A1 (en) Method For Treating Huntington's Disease by Inhibiting Dephosphorylation of Huntingtin at S421
US8273763B2 (en) Drugs for the treatment of sarcoglycanopathies
Zaratin et al. Schwann cell overexpression of the GPR7 receptor in inflammatory and painful neuropathies
US20040123334A1 (en) Methods of treating neurodegenerative diseases
US20140314790A1 (en) Caspase 9 inhibition and bri2 peptides for treating dementia
US20120076809A1 (en) Method to inhibit the biological activity of calcineurin with selective peptides
US20100316622A1 (en) Diagnosis and treatment of cardiac disorders
Hunt et al. Cyclosporin A enhances cell survival in neural precursor populations in the adult central nervous system
Polanco et al. Pituitary adenylyl cyclase activating polypeptide (PACAP) signaling and the cell cycle machinery in neurodegenerative diseases
CA2476292A1 (en) Helical peptidomimetics
JP2020529836A (ja) ミオパチーの処置における使用のためのｍｔｍｒ２−ｓポリペプチド
DE ROSA Caratterizzazione di un nuovo ruolo di CDKL5 nella sinapsi inibitoria e utilizzo di una possibile strategia terapeutica per i difetti legati alla mancanza di CDKL5
Lopes Spastin regulates microtubule dynamics and is required for normal motor and cognitive functions

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130712